Vaxcyte, Inc. (NASDAQ:PCVX) VP Jeff Fairman sold 9,500 shares of Vaxcyte stock in a transaction that occurred on Monday, June 7th. The stock was sold at an average price of $22.50, for a total value of $213,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Jeff Fairman also recently made the following trade(s):
- On Friday, March 26th, Jeff Fairman sold 4,750 shares of Vaxcyte stock. The shares were sold at an average price of $23.88, for a total value of $113,430.00.
Shares of NASDAQ:PCVX opened at $23.12 on Friday. Vaxcyte, Inc. has a fifty-two week low of $15.51 and a fifty-two week high of $58.47. The firm has a market capitalization of $1.19 billion and a PE ratio of -7.84. The business has a 50-day moving average of $19.95.
A number of large investors have recently bought and sold shares of PCVX. Pivotal bioVenture Partners Investment Advisor LLC acquired a new position in shares of Vaxcyte in the 4th quarter valued at $59,064,000. ProShare Advisors LLC bought a new position in Vaxcyte during the 4th quarter worth about $316,000. Rafferty Asset Management LLC grew its holdings in shares of Vaxcyte by 907.4% in the 1st quarter. Rafferty Asset Management LLC now owns 90,783 shares of the company’s stock valued at $1,793,000 after acquiring an additional 81,771 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new position in shares of Vaxcyte in the 4th quarter valued at about $334,000. Finally, Rhumbline Advisers grew its holdings in shares of Vaxcyte by 9.8% in the 4th quarter. Rhumbline Advisers now owns 22,397 shares of the company’s stock valued at $595,000 after acquiring an additional 1,996 shares in the last quarter. 85.68% of the stock is currently owned by hedge funds and other institutional investors.
Separately, Zacks Investment Research upgraded Vaxcyte from a “sell” rating to a “hold” rating in a research report on Tuesday, June 1st. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $48.00.
Vaxcyte Company Profile
Vaxcyte, Inc, a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis.
Read More: What does the Dogs of the Dow mean?
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.